product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
PRMT6 (D5A2N) Rabbit mAb
catalog :
14641
clonality :
monoclonal
host :
domestic rabbit
conjugate :
nonconjugated
clone name :
D5A2N
reactivity :
human, mouse
application :
western blot
more info or order :
Cell Signaling Technology product webpage
citations: 5
Published Application/Species/Sample/DilutionReference
  • western blot; human; 1:1000; loading ...; fig s1k
  • western blot; mouse; 1:1000; loading ...; fig s1l, s5f, s5m
Günes Günsel G, Conlon T, Jeridi A, Kim R, Ertuz Z, Lang N, et al. The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. Nat Commun. 2022;13:1303 pubmed publisher
  • western blot; human; 1:1000; fig 1j
Giuliani V, Miller M, Liu C, Hartono S, Class C, Bristow C, et al. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun. 2021;12:4626 pubmed publisher
  • western blot; mouse; 1:500; loading ...; fig 1b
He Y, Li W, Zheng Z, Zhao L, Li W, Wang Y, et al. Inhibition of Protein arginine methyltransferase 6 reduces reactive oxygen species production and attenuates aminoglycoside- and cisplatin-induced hair cell death. Theranostics. 2020;10:133-150 pubmed publisher
  • western blot; human; 1:5000; loading ...; fig s1b
Chen H, Lorton B, Gupta V, Shechter D. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene. 2017;36:373-386 pubmed publisher
  • western blot; human; 1:1000; fig 4
Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R. PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget. 2015;6:30957-67 pubmed publisher
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.